Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$49.82

-5.615 (-10.13%)

, MRK

Merck

$63.85

1.075 (1.71%)

15:09
10/10/16
10/10
15:09
10/10/16
15:09

Opdivo trial results may hang on Bristol-Myers shares, WSJ says

Bristol-Myers Squibb's (BMY) disappointing Opdivo trial results may continue to weigh on the shares, Charley Grant writes in the Wall Street Journal's Heard on the Street column. Grant noted that Merck (MRK) presented strong lung cancer data with its Keytruda treatment at the same meeting as Bristol-Myers and may be able to fetch outsized gains. Though Opdivo has outsold Keytruda so far, Bristol-Myers will have a difficult time meeting its growth targets if the lung cancer market slips away, the column says. Reference Link

BMY

Bristol-Myers

$49.82

-5.615 (-10.13%)

MRK

Merck

$63.85

1.075 (1.71%)

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$49.82

-5.615 (-10.13%)

09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
MRK Merck
$63.85

1.075 (1.71%)

10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

FB

Facebook

$171.11

-1.06 (-0.62%)

14:53
09/22/17
09/22
14:53
09/22/17
14:53
Periodicals
Facebook settles lawsuit over non-voting shares, Business Insider reports »

Facebook settled a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

XOP

SPDR Oil Exploration and Production Fund

$33.00

0.09 (0.27%)

14:50
09/22/17
09/22
14:50
09/22/17
14:50
Options
SPDR Oil Exploration and Production ETF puts outpace calls 6:1 »

SPDR Oil Exploration and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTXI

GTx

$8.74

0.17 (1.98%)

14:48
09/22/17
09/22
14:48
09/22/17
14:48
Conference/Events
GTx, Inc to hold a KOL luncheon meeting »

Management hosts a KOL…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EXPE

Expedia

$143.12

0.11 (0.08%)

14:45
09/22/17
09/22
14:45
09/22/17
14:45
Options
Expedia call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$74.21

-7.54 (-9.22%)

14:35
09/22/17
09/22
14:35
09/22/17
14:35
Options
Wayfair put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPPI

Spectrum

$9.81

-0.13 (-1.31%)

14:27
09/22/17
09/22
14:27
09/22/17
14:27
Hot Stocks
Spectrum lower after Twitter highlights failed trial in Korea »

Shares of Spectrum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

DLPH

Delphi

$102.58

1.54 (1.52%)

14:21
09/22/17
09/22
14:21
09/22/17
14:21
Conference/Events
Delphi to hold investor update meeting »

Investor Update Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

$NSD

NASDAQ Market Internals

14:17
09/22/17
09/22
14:17
09/22/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
09/22/17
09/22
14:16
09/22/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$117.03

0.56 (0.48%)

14:15
09/22/17
09/22
14:15
09/22/17
14:15
Options
Chevron put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 09

    Nov

S

Sprint

$8.42

0.39 (4.86%)

, TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

14:12
09/22/17
09/22
14:12
09/22/17
14:12
Periodicals
Sprint hired lobbyist tied to Trump in September, Reuters says »

Sprint (S) hired a…

S

Sprint

$8.42

0.39 (4.86%)

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    May

OPK

OPKO Health

$6.48

0.15 (2.37%)

14:05
09/22/17
09/22
14:05
09/22/17
14:05
Options
Opko Health call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

14:05
09/22/17
09/22
14:05
09/22/17
14:05
General news
Dallas Fed hawk Kaplan is open minded about one more hike »

Dallas Fed hawk Kaplan is…

GWRE

Guidewire

$78.42

1.26 (1.63%)

14:04
09/22/17
09/22
14:04
09/22/17
14:04
Conference/Events
Guidewire to host analyst day »

Analyst Day to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCPT

Four Corners Property Trust

$25.05

-0.27 (-1.07%)

, WPG

Washington Prime

$8.13

0.095 (1.18%)

14:02
09/22/17
09/22
14:02
09/22/17
14:02
Recommendations
Four Corners Property Trust, Washington Prime analyst commentary  »

Four Corners Property…

FCPT

Four Corners Property Trust

$25.05

-0.27 (-1.07%)

WPG

Washington Prime

$8.13

0.095 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$61.75

-0.76 (-1.22%)

, UNH

UnitedHealth

$188.70

-6.51 (-3.33%)

14:02
09/22/17
09/22
14:02
09/22/17
14:02
Hot Stocks
Health insurers jump as McCain comes out against latest repeal/replace effort »

Shares of a number of…

MOH

Molina Healthcare

$61.75

-0.76 (-1.22%)

UNH

UnitedHealth

$188.70

-6.51 (-3.33%)

CNC

Centene

$87.58

-3.16 (-3.48%)

WCG

WellCare

$163.07

-2.99 (-1.80%)

CI

Cigna

$181.14

-0.99 (-0.54%)

ANTM

Anthem

$181.21

-2.29 (-1.25%)

HNT

Health Net

HUM

Humana

$235.79

-2.85 (-1.19%)

AET

Aetna

$150.76

-2.63 (-1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

ICPT

Intercept

$73.70

-24.42 (-24.89%)

13:57
09/22/17
09/22
13:57
09/22/17
13:57
Downgrade
Intercept rating change  »

Oppenheimer downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$46.29

0.87 (1.92%)

13:57
09/22/17
09/22
13:57
09/22/17
13:57
Hot Stocks
Trump thanks American Airlines for 'fantastic job' with hurricane flights »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

IWM

iShares Trust Russell 2000 Index Fund

$144.38

0.69 (0.48%)

, RUT

Russell 2000 Index

13:53
09/22/17
09/22
13:53
09/22/17
13:53
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT) is…

IWM

iShares Trust Russell 2000 Index Fund

$144.38

0.69 (0.48%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$61.77

-0.74 (-1.18%)

, UNH

UnitedHealth

$189.08

-6.13 (-3.14%)

13:53
09/22/17
09/22
13:53
09/22/17
13:53
Periodicals
McCain says cannot vote for Graham-Cassidy healthcare bill, Bloomberg reports »

Publicly traded companies…

MOH

Molina Healthcare

$61.77

-0.74 (-1.18%)

UNH

UnitedHealth

$189.08

-6.13 (-3.14%)

CNC

Centene

$87.61

-3.13 (-3.45%)

WCG

WellCare

$162.70

-3.36 (-2.02%)

CI

Cigna

$181.18

-0.9483 (-0.52%)

ANTM

Anthem

$181.24

-2.26 (-1.23%)

HNT

Health Net

HUM

Humana

$235.91

-2.735 (-1.15%)

AET

Aetna

$150.81

-2.58 (-1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 24

    Oct

  • 08

    Nov

XLE

Energy Select Sector SPDR

$67.08

0.22 (0.33%)

, XLI

Industrial Select Sector SPDR

$70.76

0.19 (0.27%)

13:51
09/22/17
09/22
13:51
09/22/17
13:51
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

For the week, the S&P…

XLE

Energy Select Sector SPDR

$67.08

0.22 (0.33%)

XLI

Industrial Select Sector SPDR

$70.76

0.19 (0.27%)

XLF

Financial Select Sector

$25.43

-0.035 (-0.14%)

XLB

S&P Select Materials SPDR

$56.57

-0.18 (-0.32%)

XLP

Consumer Staples Sector SPDR

$53.97

-0.115 (-0.21%)

XLU

Utilities SPDR

$53.43

-0.24 (-0.45%)

XLV

Health Care Select Sector SPDR

$81.25

-0.33 (-0.40%)

SPY

SPDR S&P 500 ETF Trust

$249.16

-0.23 (-0.09%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$54.07

0.16 (0.30%)

, UGI

UGI Corporation

$47.06

-0.28 (-0.59%)

13:50
09/22/17
09/22
13:50
09/22/17
13:50
Periodicals
Total sells Total Italia Gas to UGI Corporation, Reuters reports »

Total (TOT) has sold its…

TOT

Total

$54.07

0.16 (0.30%)

UGI

UGI Corporation

$47.06

-0.28 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$21.56

0.3975 (1.88%)

13:50
09/22/17
09/22
13:50
09/22/17
13:50
Options
One-week option play opened in Macy's »

One-week option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

ICPT

Intercept

13:48
09/22/17
09/22
13:48
09/22/17
13:48
Downgrade
Intercept rating change  »

Intercept downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXAS

Exact Sciences

$45.00

1.6 (3.69%)

13:40
09/22/17
09/22
13:40
09/22/17
13:40
Options
Longer-term spread opened in Exact Sciences »

Longer-term spread opened…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.